BACKGROUND: We sought to describe the epidemiology and risk factors for Clostridium difficile infection (CDI) among kidney transplant recipients (KTR) between 1 January 2008 and 31 December 2010. METHODS: A single-institution retrospective study was conducted among all adult KTR with CDI, defined as a positive test for C. difficile by a cell cytotoxic assay for C. difficile toxin A or B or polymerase chain reaction test for toxigenic C. difficile. RESULTS: Among 603 kidney transplants performed between 1 January 2008 and 31 December 2010, 37 (6.1%) patients developed CDI: 12 (of 128; 9.4%) high-risk (blood group incompatible and/or anti-human leukocyte antigen donor-specific antibodies) vs. 25 (of 475; 5.3%, P = 0.08) standard-risk patients. The overall rate of CDI increased from 3.7% in 2008 to 9.4% in 2010 (P = 0.05). The median time to CDI diagnosis was 9 days, with 27 (73.0%) patients developing CDI within the first 30 days after their transplant, and 14 (51.8%) developing CDI within 7 days. A case-control analysis of 37 CDI cases and 74 matched controls demonstrated the following predictors for CDI among KTR: vancomycin-resistant Enterococcus colonization before transplant (odds ratio [OR]: 3.6, P = 0.03), receipt of an organ from Centers for Disease Control high-risk donor (OR: 5.9, P = 0.006), and administration of high-risk antibiotics within 30 days post transplant (OR: 6.6, P = 0.001). CONCLUSIONS: CDI remains a common early complication in KTR, with rates steadily increasing during the study period. Host and transplant-related factors and exposure to antibiotics appeared to significantly impact the risk for CDI among KTR.
BACKGROUND: We sought to describe the epidemiology and risk factors for Clostridium difficileinfection (CDI) among kidney transplant recipients (KTR) between 1 January 2008 and 31 December 2010. METHODS: A single-institution retrospective study was conducted among all adult KTR with CDI, defined as a positive test for C. difficile by a cell cytotoxic assay for C. difficile toxin A or B or polymerase chain reaction test for toxigenic C. difficile. RESULTS: Among 603 kidney transplants performed between 1 January 2008 and 31 December 2010, 37 (6.1%) patients developed CDI: 12 (of 128; 9.4%) high-risk (blood group incompatible and/or anti-human leukocyte antigen donor-specific antibodies) vs. 25 (of 475; 5.3%, P = 0.08) standard-risk patients. The overall rate of CDI increased from 3.7% in 2008 to 9.4% in 2010 (P = 0.05). The median time to CDI diagnosis was 9 days, with 27 (73.0%) patients developing CDI within the first 30 days after their transplant, and 14 (51.8%) developing CDI within 7 days. A case-control analysis of 37 CDI cases and 74 matched controls demonstrated the following predictors for CDI among KTR: vancomycin-resistant Enterococcus colonization before transplant (odds ratio [OR]: 3.6, P = 0.03), receipt of an organ from Centers for Disease Control high-risk donor (OR: 5.9, P = 0.006), and administration of high-risk antibiotics within 30 days post transplant (OR: 6.6, P = 0.001). CONCLUSIONS: CDI remains a common early complication in KTR, with rates steadily increasing during the study period. Host and transplant-related factors and exposure to antibiotics appeared to significantly impact the risk for CDI among KTR.
Authors: B S Bender; R Bennett; B E Laughon; W B Greenough; C Gaydos; S D Sears; M S Forman; J G Bartlett Journal: Lancet Date: 1986-07-05 Impact factor: 79.321
Authors: K Keven; A Basu; L Re; H Tan; A Marcos; J J Fung; T E Starzl; R L Simmons; R Shapiro Journal: Transpl Infect Dis Date: 2004-03 Impact factor: 2.228
Authors: Julia Origüen; Mario Fernández-Ruiz; Carlos Lumbreras; María Ángeles Orellana; Francisco López-Medrano; Tamara Ruiz-Merlo; Rafael San Juan; Ana García-Reyne; Esther González; Natalia Polanco; Estela Paz-Artal; Amado Andrés; José María Aguado Journal: Infection Date: 2015-02-13 Impact factor: 3.553
Authors: Carolyn D Alonso; Simon F Dufresne; David B Hanna; Annie-Claude Labbé; Suzanne B Treadway; Dionissios Neofytos; Sylvie Bélanger; Carol Ann Huff; Michel Laverdière; Kieren A Marr Journal: Biol Blood Marrow Transplant Date: 2013-08-01 Impact factor: 5.742
Authors: Suresh Paudel; Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Eleftherios Mylonakis Journal: PLoS One Date: 2015-04-17 Impact factor: 3.240
Authors: Seyed M Hosseini-Moghaddam; Bin Luo; Sarah E Bota; Shahid Husain; Michael S Silverman; Nick Daneman; Kevin A Brown; J Michael Paterson Journal: JAMA Netw Open Date: 2021-12-01
Authors: Juthaporn Cowan; Alexandria Bennett; Nicholas Fergusson; Cheynne McLean; Ranjeeta Mallick; D William Cameron; Greg Knoll Journal: Can J Kidney Health Dis Date: 2018-09-12